| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T271 |
0-88 |
Sentence |
denotes |
HCQ exerts anticancer effects by acting synergistically with common chemotherapic drugs. |
| T272 |
89-286 |
Sentence |
denotes |
Although it has a well-defined and favorable toxicity profile, the necessity of increasing the dose, in some cases, limits the utilization, due to the toxicity, mainly at cardiac and ocular levels. |
| T273 |
287-394 |
Sentence |
denotes |
A two-compartment model, with first-order absorption and a lag time, describes the pharmacokinetics of HCQ. |
| T274 |
395-515 |
Sentence |
denotes |
The long-terminal half-life prolongs the time to reach steady-state concentrations, then delays the therapeutic effects. |
| T275 |
516-594 |
Sentence |
denotes |
The next-generation formulations allow modulating the pharmacokinetics of HCQ. |
| T276 |
595-734 |
Sentence |
denotes |
Avoiding systemic absorption, then liver first-pass metabolism, HCQ may be used in site-specific inflammation, without toxicity [72,73,74]. |
| T277 |
735-859 |
Sentence |
denotes |
The selected studies’ primary outcomes are the extent to which HCQ may limit disease progression or exacerbations (Table 2). |
